{"nctId":"NCT01387230","briefTitle":"Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD","startDateStruct":{"date":"2011-07-01"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":206,"armGroups":[{"label":"GSK573719","type":"EXPERIMENTAL","interventionNames":["Drug: GSK573719"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"GSK573719","otherNames":[]},{"name":"GSK573719","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of COPD\n* 10 pack-year or greater history of cigarette smoking\n* Post-bronchodilator FEV1/FVC of \\<0.7\n* Predicted FEV1 of 70% of normal or less\n* Modified Medical Research Council (mMRC) dyspnea score of 2 or greater\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating, or planning to become pregnant\n* Respiratory disorders other than COPD, including a current diagnosis of asthma\n* Clinically significant non-respiratory diseases or abnormalities that are not adequately controlled\n* Significant allergy or hypersensitivity to anticholinergics, beta2-agonists, or the excipients of magnesium stereate or lactose used in the inhaler delivery device\n* Hospitalization for COPD or pneumonia within 12 weeks prior to screening\n* Lung volume reduction surgery within 12 weeks prior to screening\n* Abnormal and clinically significant ECG findings at screening\n* Clinically significant laboratory findings at screening\n* Use of systemic corticosteroids, antibiotics for respiratory tract infections, high dose inhaled steroids (\\>1000mcg fluticasone propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled beta2-agonists, inhaled sodium cromoglycate or nedocromil sodium, or investigational medicines for defined time periods prior to the screening visit\n* Use of long-term oxygen therapy (12 hours or greater per day)\n* Regular use of nebulized treatment with short-acting bronchodilators\n* Participation in the acute phase of a pulmonary rehabilitation program\n* A know or suspected history of alcohol or drug abuse\n* Affiliation with the investigational site\n* Previous use of GSK573719 or the combination of GSK573719/GW642444","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85","description":"FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 14, 28, 56, 84, and 85. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 85 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 84). Change from Baseline was calculated as the trough FEV1 minus the Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.007","spread":"0.0280"},{"groupId":"OG001","value":"0.120","spread":"0.0257"},{"groupId":"OG002","value":"0.145","spread":"0.0268"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Days 1, 28 (Week 4) and 84 (Week 12)","description":"FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, and Day 84 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \\[min\\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 1 hour, 3 hours, and 6 hours. Change from Baseline was the WM minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.017","spread":"0.0150"},{"groupId":"OG001","value":"0.141","spread":"0.0147"},{"groupId":"OG002","value":"0.164","spread":"0.0147"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.024","spread":"0.0223"},{"groupId":"OG001","value":"0.141","spread":"0.0206"},{"groupId":"OG002","value":"0.172","spread":"0.0212"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.003","spread":"0.0271"},{"groupId":"OG001","value":"0.163","spread":"0.0248"},{"groupId":"OG002","value":"0.188","spread":"0.0256"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serial FEV1 Over 24 Hours Post-dose at Days 1 and 84 (Week 12)","description":"Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry. Serial FEV1 measurements of interest for Day 1 were collected at 1, 3, 6, 23 and 24 hours post-dose on Day 1 and for Day 84, the measures were pre-dose (24 hours post-dose of Day 83 morning dose but prior to Day 84's dose) and 1, 3, 6, 23 and 24 hours post dose on Day 84. Baseline is the mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1. Change from Baseline was calculated as FEV1 value at the evaluated time point minus Baseline. Analysis performed separately by Visit/Day using a repeated measures model with covariates of treatment, Baseline, smoking status, center group, time, time by Baseline and time by treatment interactions.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.001","spread":"0.0148"},{"groupId":"OG001","value":"0.132","spread":"0.0147"},{"groupId":"OG002","value":"0.142","spread":"0.0147"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":"0.0187"},{"groupId":"OG001","value":"0.165","spread":"0.0186"},{"groupId":"OG002","value":"0.210","spread":"0.0186"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.0206"},{"groupId":"OG001","value":"0.156","spread":"0.0203"},{"groupId":"OG002","value":"0.169","spread":"0.0203"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.027","spread":"0.0178"},{"groupId":"OG001","value":"0.070","spread":"0.0176"},{"groupId":"OG002","value":"0.113","spread":"0.0180"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.020","spread":"0.0190"},{"groupId":"OG001","value":"0.099","spread":"0.0188"},{"groupId":"OG002","value":"0.151","spread":"0.0191"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":"0.0299"},{"groupId":"OG001","value":"0.155","spread":"0.0269"},{"groupId":"OG002","value":"0.177","spread":"0.0283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.025","spread":"0.0299"},{"groupId":"OG001","value":"0.167","spread":"0.0270"},{"groupId":"OG002","value":"0.199","spread":"0.0283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.012","spread":"0.0301"},{"groupId":"OG001","value":"0.189","spread":"0.0271"},{"groupId":"OG002","value":"0.219","spread":"0.0285"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.0286"},{"groupId":"OG001","value":"0.159","spread":"0.0257"},{"groupId":"OG002","value":"0.178","spread":"0.0270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.019","spread":"0.0301"},{"groupId":"OG001","value":"0.106","spread":"0.0271"},{"groupId":"OG002","value":"0.142","spread":"0.0286"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.0299"},{"groupId":"OG001","value":"0.142","spread":"0.0269"},{"groupId":"OG002","value":"0.170","spread":"0.0284"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":68},"commonTop":["Nasopharyngitis","Headache","Back pain","Cough"]}}}